EU Prescribing Patterns for Rituximab Biosimilars in Non-Hodgkin Lymphoma

June 28, 2018 – European patients with non-Hodgkin lymphoma (NHL) are more likely to be prescribed a rituximab biosimilar if they are in better overall health, have indolent histology, and have follicular lymphoma, according to a study presented at the 2018 ASCO Annual Meeting. Further, in the United Kingdom and Germany, the 2 countries with the highest use of rituximab biosimilars, prescription rates for the biosimilars were higher in treatment lines beyond the frontline … (leggi tutto)